Chelation therapy uses molecules with high affinity for specific metal ions to form stable, excretable complexes, removing toxic metals from the body. The word derives from Greek "chele" (claw) — the chelator grips the metal ion at multiple coordination sites. While chelation is life-saving in acute poisoning, its application in chronic low-level exposure and complex diseases remains controversial, and the risks of mis metallation and essential metal depletion are non-trivial.
Major Chelating Agents
EDTA (Ethylenediaminetetraacetic acid)
- Target metals: Lead, cadmium, zinc, calcium
- Route: IV infusion (CaNa2EDTA to avoid hypocalcemia)
- Clinical use: Acute lead poisoning; the TACT trial showed modest benefit in post-MI diabetic patients with elevated lead
- Limitations: Poor oral bioavailability; non-selective (depletes Zn, Cu, Mn)
DMSA (Succimer / Dimercaptosuccinic acid)
- Target metals: Lead, mercury, arsenic
- Route: Oral
- Clinical use: FDA-approved for lead poisoning in children (blood Pb >45 mcg/dL). First-line pediatric chelator due to oral administration and relative safety.
- Limitations: Does not cross blood-brain barrier effectively; may redistribute metals if given before source removal
DMPS (2,3-Dimercapto-1-propanesulfonic acid / Unithiol)
- Target metals: Mercury (especially inorganic), arsenic, lead
- Route: Oral or IV
- Clinical use: Mercury poisoning (preferred over DMSA for inorganic Hg); arsenic poisoning. Not FDA-approved in the US but used widely in Europe.
- Limitations: Can mobilize mercury from tissue stores; renal excretion requires adequate kidney function
D-Penicillamine
- Target metals: Copper, lead, mercury
- Route: Oral
- Clinical use: Wilson's disease (copper overload) — historical first-line agent. Also used in lead and mercury poisoning when DMSA/DMPS unavailable.
- Limitations: Significant side effects (nephrotoxicity, bone marrow suppression, autoimmune reactions); largely supplanted by trientine for Wilson's disease
Deferoxamine (Desferal)
- Target metals: Iron
- Route: SC or IV infusion (poorly absorbed orally)
- Clinical use: Acute iron poisoning; chronic iron overload from transfusion-dependent thalassemia. The siderophore-derived chelator with highest iron specificity.
- Limitations: Requires prolonged infusion (8-12 hrs SC); ototoxicity, retinal toxicity with chronic use
Deferasirox (Exjade/Jadenu)
- Target metals: Iron
- Route: Oral (once daily)
- Clinical use: Chronic transfusional iron overload. Revolutionized iron chelation by replacing deferoxamine infusions with oral dosing.
- Limitations: Hepatotoxicity, nephrotoxicity; GI side effects; expensive
Disulfiram / Diethyldithiocarbamate (DDC)
- Target metals: Nickel, copper
- Route: Oral
- Clinical use: Nickel carbonyl poisoning (the specific antidote). DDC, the active metabolite of disulfiram (Antabuse), chelates Ni(II) with high affinity. Also explored for copper chelation in cancer therapy.
- Limitations: Disulfiram-alcohol reaction; hepatotoxicity; limited clinical experience outside nickel carbonyl poisoning
When Chelation Is Appropriate
- Acute poisoning with confirmed toxic metal levels above treatment thresholds
- Chronic overload with documented tissue accumulation (e.g., transfusional iron overload, Wilson's disease)
- Symptomatic exposure where metal levels correlate with clinical findings and source has been removed
Risks and Controversies
Essential Metal Depletion
No chelator is perfectly selective. EDTA depletes zinc and calcium. DMSA can lower zinc and copper. Deferoxamine given to iron-replete individuals causes iron deficiency. This creates a paradox: chelation of one toxic metal may induce deficiency of another essential metal, potentially worsening disease through mis metallation.
Redistribution
Chelators can mobilize metals from stable tissue depots into the bloodstream, potentially increasing exposure to vulnerable organs (especially the brain) before the complex is excreted. This is particularly concerning for mercury and lead.
The Autism Controversy
Chelation therapy has been promoted in alternative medicine for autism spectrum disorder based on the theory that mercury (from thimerosal in vaccines) causes autism. Multiple systematic reviews find no evidence supporting this practice. The FDA has warned against over-the-counter chelation products. At least one child death has been attributed to inappropriate EDTA chelation.
Chelation vs. Microbiome
An underexplored dimension: chelation alters luminal metal availability, which directly impacts the gut metal microbiome. Removing iron via chelation could starve iron-dependent pathobionts but also deprive beneficial lactobacillus species. The microbiome consequences of chelation therapy remain largely unstudied.
Metal-Specific Protocols
| Metal | First-Line Chelator | Alternative | Key Consideration |
|---|---|---|---|
| Lead (adult) | CaNa2EDTA | DMSA | Remove source first |
| Lead (child) | DMSA (succimer) | CaNa2EDTA | Threshold: blood Pb >45 mcg/dL |
| Mercury (inorganic) | DMPS | DMSA | Monitor renal function |
| Mercury (organic/methyl) | DMSA | None well-established | Poor CNS penetration limits efficacy |
| Arsenic | DMPS or DMSA | BAL (dimercaprol) | BAL is older, more toxic |
| Iron (acute) | Deferoxamine | — | Vin rose urine confirms chelation |
| Iron (chronic) | Deferasirox | Deferoxamine | Oral vs. infusion trade-off |
| Copper (Wilson's) | Trientine or D-penicillamine | Zinc (maintenance) | Zinc blocks absorption long-term |
| Nickel (Ni carbonyl) | Disulfiram/DDC | — | Specific antidote |
See Also
- mis metallation — the fundamental problem chelation can cause
- environmental metal exposure — source identification before chelation
- iron / copper / lead / mercury / arsenic / nickel — individual metal pages
- gut metal microbiome — unexplored microbiome effects of chelation